{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T22:47:25Z","timestamp":1781304445525,"version":"3.54.1"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.jneuroim.2015.08.003","type":"journal-article","created":{"date-parts":[[2015,8,8]],"date-time":"2015-08-08T07:35:50Z","timestamp":1439019350000},"page":"29-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Favorable outcome of granulocyte colony-stimulating factor use in neuromyelitis optica patients presenting with agranulocytosis in the setting of rituximab"],"prefix":"10.1016","volume":"287","author":[{"given":"Maureen A.","family":"Mealy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2015.08.003_bb0005","first-page":"616787","article-title":"Early-onset neutropenia induced by rituximab in a patient with lupus nephritis and hemolytic anemia","volume":"2015","author":"Arroyo-\u00c1vila","year":"2015","journal-title":"Case Rep. Rheumatol."},{"key":"10.1016\/j.jneuroim.2015.08.003_bb0010","first-page":"345","article-title":"Early onset neutropenia after rituximab in lupus nephritis","volume":"25","author":"Enr\u00edquez","year":"2007","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jneuroim.2015.08.003_bb0015","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1365-2133.2007.07800.x","article-title":"Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients","volume":"156","author":"Goh","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jneuroim.2015.08.003_bb0020","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/ard.2004.029694","article-title":"Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases","volume":"64","author":"Gottenberg","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jneuroim.2015.08.003_bb0025","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1177\/1352458512443994","article-title":"Detrimental role of granulocyte-colony stimulating factor in neuromyelitis optica: clinical case and histological evidence","volume":"18","author":"Jacob","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2015.08.003_bb0030","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.msard.2013.08.001","article-title":"Late-onset neutropenia during long-term rituximab therapy in neuromyelitis optica","volume":"3","author":"Plate","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2015.08.003_bb0035","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/art.30427","article-title":"Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections","volume":"63","author":"Tesfa","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jneuroim.2015.08.003_bb0040","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2015.08.003_bb0045","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2015.08.003_bb0050","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/MD.0b013e3181f2caef","article-title":"Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature","volume":"89","author":"Wolach","year":"2010","journal-title":"Medicine (Baltimore)"}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572815300175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572815300175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:25:44Z","timestamp":1759047944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572815300175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":10,"alternative-id":["S0165572815300175"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2015.08.003","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Favorable outcome of granulocyte colony-stimulating factor use in neuromyelitis optica patients presenting with agranulocytosis in the setting of rituximab","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2015.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}